Stock listing

Dusseldorf:5DT Entera Bio Ltd. Aktie

German listing (Dusseldorf) of Entera Bio Ltd. · home listing NASDAQ:ENTX

Follow Entera Bio Ltd. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ENTX

$3.31 USD +0.05 (+1.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ENTX

Past year +28.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.18 – $3.33 USDNov 20, 2026
Volume
469,047 sharesNov 20, 2026
Market cap
$574.8M USDAt the close on Nov 20, 2026 · price × 173.9M shares outstanding
52-week range
$0.91 – $4.20 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.28M USDMedian day 329,883 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Entera Bio Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ENTX · Home$3.305 USD+0.045 (+1.4%)469,047$3.25$3.33$3.175$3.26Close on Nov 20, 2026
Frankfurt:5DT€2.88 EUR0.00 (0.0%)—€2.88€2.88€2.88€2.88Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ENTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.305+0.045+1.4%$3.25$3.33$3.175469,047
$3.26+0.26+8.7%$3.03$3.27$3.00493,477
$3.00-0.02-0.7%$3.05$3.10$3.00187,391
$3.02-0.09-2.9%$3.11$3.117$3.00208,609
$3.11-0.11-3.4%$3.22$3.265$3.08155,334
$3.220.000.0%$3.20$3.24$3.13170,483
$3.22-0.02-0.6%$3.275$3.275$3.13103,427
$3.24-0.01-0.3%$3.25$3.25$3.1798,553
$3.25+0.11+3.5%$3.17$3.488$3.11512,162
$3.14+0.15+5.0%$3.03$3.18$2.91118,328
$2.99-0.12-3.9%$3.07$3.10$2.90219,761
$3.11+0.06+2.0%$3.05$3.20$3.05291,239
$3.05-0.04-1.3%$3.06$3.12$2.99136,933
$3.09-0.11-3.4%$3.19$3.29$2.99329,883
$3.20+0.08+2.6%$3.06$3.24$2.95292,681
$3.12+0.02+0.6%$3.08$3.189$3.01140,950
$3.10+0.04+1.3%$3.05$3.195$3.005181,559
$3.06+0.20+7.0%$2.85$3.13$2.81203,525
$2.86-0.06-2.1%$2.90$2.90$2.80232,466
$2.92-0.10-3.3%$2.99$3.02$2.86256,927
$3.02-0.03-1.0%$3.01$3.04$2.901629,476
$3.05+0.03+1.0%$3.12$3.20$2.96784,597
$3.02+0.08+2.7%$2.79$3.26$2.79791,927
$2.94+0.26+9.7%$2.66$2.97$2.62953,139
$2.68-0.09-3.2%$2.72$2.75$2.62572,891
$2.77+0.27+10.8%$2.49$2.82$2.491,447,906
$2.50+0.01+0.4%$2.47$2.565$2.46784,486
$2.49-0.16-6.0%$2.65$2.65$2.435755,300
$2.65-0.01-0.4%$2.66$2.775$2.639305,688
$2.66+0.16+6.4%$2.51$2.72$2.5051,584,092
$2.50-0.01-0.4%$2.48$2.52$2.45421,033
$2.51-0.02-0.8%$2.52$2.58$2.45679,477
$2.53-0.09-3.4%$2.66$2.67$2.53621,167
$2.62-0.24-8.4%$2.89$2.89$2.621,254,986
$2.86-0.03-1.0%$2.89$2.90$2.82100,700
$2.89-0.02-0.7%$2.89$3.00$2.81640,880
$2.91+0.22+8.2%$2.67$2.975$2.57520,976
$2.690.000.0%$2.70$2.72$2.66160,845
$2.69-0.055-2.0%$2.80$2.89$2.645340,910
$2.745-0.055-2.0%$2.91$2.91$2.70776,301
$2.80-0.01-0.4%$2.78$2.88$2.71234,000
$2.81-0.17-5.7%$3.01$3.01$2.70858,157
$2.98+0.02+0.7%$3.02$3.03$2.945613,718
$2.960.000.0%$2.93$2.97$2.86294,685
$2.96-0.07-2.3%$3.14$3.14$2.88288,975
$3.03+0.07+2.4%$2.95$3.05$2.94310,173
$2.96+0.10+3.5%$2.86$3.05$2.785777,611
$2.86+0.04+1.4%$2.77$2.86$2.68391,364
$2.82-0.02-0.7%$2.81$2.90$2.76100,044
$2.84+0.05+1.8%$2.85$2.94$2.825187,608
$2.79-0.05-1.8%$2.82$2.85$2.72437,618
$2.84-0.17-5.6%$2.99$3.04$2.83622,167
$3.01+0.01+0.3%$2.95$3.07$2.82824,636
$3.00+0.05+1.7%$2.95$3.15$2.88606,922
$2.95+0.03+1.0%$2.99$3.025$2.90154,038
$2.92+0.02+0.7%$2.90$3.00$2.84143,497
$2.90-0.05-1.7%$2.94$3.09$2.80256,682
$2.95-0.08-2.6%$3.03$3.09$2.915214,454
$3.03-0.05-1.6%$3.12$3.15$3.00138,183
$3.08-0.11-3.4%$3.20$3.41$3.03240,676
$3.19-0.28-8.1%$3.46$3.47$3.10523,310
$3.47+0.05+1.5%$3.42$3.56$3.405429,970
$3.42+0.19+5.9%$3.28$3.47$3.20258,132
$3.23+0.01+0.3%$3.22$3.34$3.14441,300
$3.22+0.11+3.5%$3.01$3.33$3.00468,467
Ticker
Dusseldorf:5DT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Dusseldorf
Currency
EUR

What changed lately

Latest news

All Entera Bio Ltd. news

Entera Bio Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
30 in the last 12 months · 141 in all · newest Nov 6, 2026 · oldest 2019
Calls
5 calls with a replay · 5 with a transcript · latest May 18, 2022
Decks
10 decks · latest September 2025

Where Entera Bio Ltd. is listed

ListingExchangeCountryCurrency
NASDAQ:ENTX · Home listingNASDAQUnited StatesUSD
LS Exchange:A2JQXPLS ExchangeGermanyEUR
Lang & Schwarz:A2JQXPLang & SchwarzGermanyEUR
Stuttgart:5DTStuttgartGermanyEUR
BOATS:ENTXBOATSUnited StatesUSD
Tradegate:5DTTradegateGermanyEUR
Dusseldorf:5DT · This pageDusseldorfGermanyEUR
Frankfurt:5DTFrankfurtGermanyEUR
Hamburg:5DTHamburgGermanyEUR

Valuation

Price/book 2.1× against a median of 2.3×: 6th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$308.9M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
2.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.76

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Entera Bio Ltd. · NASDAQ:ENTXUS$574.8MUS$308.9Mn/an/an/a2.1×n/a0.0×0.76
Annexon, Inc. · NASDAQ:ANNXUS$587.7MUS$423.7Mn/an/an/a4.1×n/a0.3×1.63
Design Therapeutics, Inc. · NASDAQ:DSGNUS$577.6MUS$371.5Mn/an/an/a2.9×n/a0.0×1.29
Cullinan Therapeutics, Inc. · NASDAQ:CGEMUS$577.1MUS$289.6Mn/an/an/a2.0×n/a0.0×1.45
Immix Biopharma, Inc. · NASDAQ:IMMXUS$577.0MUS$241.7Mn/an/an/a1.7×n/a0.0×1.60
DBV Technologies SA · EURONEXT:DBVUS$571.8MUS$430.7Mn/a47.1×n/a3.9×n/a0.1×n/a
Ascletis Pharma, Inc. · HKEX:1672US$571.4MUS$231.6Mn/a761×n/a1.7×n/a0.0×n/a
4D Molecular Therapeutics, Inc. · NASDAQ:FDMTUS$565.1MUS$277.8Mn/a2.9×n/a1.7×−208.6%0.1×1.75
Bicara Therapeutics Inc. · NASDAQ:BCAXUS$560.3MUS$118.8Mn/an/an/a1.4×n/a0.0×1.37
Lepu Biopharma Co. Ltd. Class H · HKEX:2157US$554.8MUS$613.5M14.5×4.5×22.9×2.6×28.0%0.8×n/a
Aclaris Therapeutics, Inc. · NASDAQ:ACRSUS$545.6MUS$431.3Mn/a67.4×n/a3.3×n/a0.0×1.42
Median of the othersUS$571.6MUS$330.5M14.5×47.1×22.9×2.3×−90.3%0.0×1.45

Forecasts

5 strong buy · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
9.75 USD · Analysts' mean
EPS, year to Dec 2026
-0.42 · 4 analysts

Team and board

Officers

OfficerRole
Miranda ToledanoChief Executive Officer and Board Member
Dana-Garbeli YaacovChief Financial Officer
Hillel GalitzerChief Operating Officer
Anke HoppeVP of Clinical Operations
Cherin SmithSVP Clinical Operations
Michele McDermottSVP Medical Affairs
Gregory BurshteinChief Scientific Officer
Michal KushnirHead of Program Management
Osnat Bar-PeledExecutive Director of IP
Rachel B. WagmanChief Clinical Advisor
Riccardo Paolo CamisascaChief Medical Officer

Board

DirectorRole
Geno J. GermanoChairman of the Board
Gerald LiebermanDirector
Gerald M. OstrovBoard Member
Haya TaitelBoard Member
Miranda ToledanoChief Executive Officer and Board Member
Sean EllisBoard Member
Steve Rubin
Yonatan MalcaBoard Member

Events

Calls

CallWhenStatus
Entera Bio (NASDAQ:ENTX) Q1 2022 Earnings CallWed, May 18, 2022 · 8:00 AM ETReplay
Entera Bio (NASDAQ:ENTX) Q4 2021 Earnings CallTue, Mar 08, 2022 · 8:30 AM ETReplay
Entera Bio (NASDAQ:ENTX) Q2 2021 Earnings CallMon, Aug 16, 2021 · 8:30 AM ETReplay
Entera Bio (NASDAQ:ENTX) Q1 2021 Earnings CallThu, May 20, 2021 · 8:30 AM ETReplay
Entera Bio (NASDAQ:ENTX) Q4 2020 Earnings CallThu, Mar 18, 2021 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 6, 2026 · After close+3.5%
Q2 2026Aug 7, 2026+7.8%
Q1 2026May 8, 2026 · After close−10.0%
Q4 2025Mar 27, 2026−2.9%
Q3 2025Nov 14, 2025 · After close−1.1%
Q2 2025Aug 8, 2025 · After close+3.3%
Q1 2025May 9, 2025 · After close0.0%
Q4 2024Mar 6, 2025 · Before open−3.6%
Q3 2024Nov 8, 2024 · After close−1.2%
Q2 2024Aug 9, 2024 · After close−2.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 10, 2024 · After close−4.9%
Q4 2023Mar 8, 2024 · After close+5.0%
Q3 2023Nov 14, 2023 · Before open+2.9%
Q2 2023Aug 11, 2023 · After close−17.6%
Q1 2023May 5, 2023 · After close+7.3%
Q4 2022Mar 31, 2023 · After close−13.4%
Q3 2022Nov 10, 2022 · After close−19.2%
Q2 2022Aug 11, 2022 · Before open+1.6%
Q1 2022May 12, 2022 · Before open+4.5%
Q4 2021Mar 8, 2022 · Before open−4.0%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (September 2025)Technical19 slidesSeptember 2025
Technical Presentation (July 2025)Technical14 slidesJuly 2025
Investor Presentation (September 2023)Investor deck36 slidesSeptember 2023
Investor Presentation (March 2023)Investor deck33 slidesMarch 2023
Investor Presentation (November 2022)Investor deck34 slidesNovember 2022
Investor Presentation (November 2022)Investor deck35 slidesNovember 2022
Investor Presentation (November 2022)Investor deck34 slidesNovember 2022
Investor Presentation (August 2022)Investor deck34 slidesAug 1, 2022
Technical Presentation (2021)Technical15 slides2021
Investor PresentationInvestor deck39 slides

Open Decks

Financings

RaiseDate
Private placement of ordinary shares and pre-funded warrants
Closed: US$275M raised · US$2.04 a share · Leerink Partners +5
Dealers: Leerink Partners (lead), Evercore ISI, Guggenheim Securities, Cantor, LifeSci Capital, Canaccord Genuity
Buyers: BVF Partners L.P. (led the private placement; granted the right to designate two directors); Longitude Capital; Vivo Capital; TCGX; Spruce Street Capital; Venrock Healthcare Capital Partners; RA Capital Management; Perceptive Advisors; Driehaus Capital Management; Logos Capital; Catalio Capital Management
Use of proceeds: Fund EB613 Phase 3 program through NDA submission, advance EB612 into the clinic with OPKO, and extend cash runway into 2030
Aug 7, 2026
Strategic investment of ordinary shares
Closed: US$2.17 a share
Buyers: OPKO (3,685,226 ordinary shares at $2.17 per share)
Use of proceeds: To fund Entera's 40% share of costs of the oral GLP-1/glucagon program through Phase 1
Mar 17, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$8.00 a unit on Jun 27, 2018.

Price
US$8.00 a unit
Shares offered
1,400,000 ordinary shares
Offering size
US$11.2 million
Underwriters' option
Up to 210,000 more shares
Listing
ENTX on the Nasdaq Capital Market
Underwriters
Maxim Group LLC, Joseph Gunnar & Co. · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceJul 14, 2017
Filed publiclyNov 9, 2017
Amended 7 timesNewest Jun 27, 2018
Shares registered with an exchangeJun 25, 2018
Declared effective by the SECJun 27, 2018
Final prospectus, with the priceJun 29, 2018

Filings

FilingFiled
424B4 · ProspectusJun 29, 2018
EFFECT · Notice that a registration is effectiveJun 27, 2018
F-1/A · Registration statement, amendedJun 27, 2018
CORRESP · Letter to the SECJun 26, 2018
CERT · Exchange's certificate of listingJun 26, 2018
UPLOAD · Letter from the SECJun 26, 2018
CORRESP · Letter to the SECJun 25, 2018
CORRESP · Letter to the SECJun 25, 2018
8-A12B · Registration of shares for listing on an exchangeJun 25, 2018
CORRESP · Letter to the SECJun 25, 2018
All 34 filings
FilingFiled
F-1/A · Registration statement, amendedJun 25, 2018
UPLOAD · Letter from the SECJun 22, 2018
CORRESP · Letter to the SECJun 15, 2018
F-1/A · Registration statement, amendedJun 15, 2018
UPLOAD · Letter from the SECJun 12, 2018
F-1/A · Registration statement, amendedMay 17, 2018
CORRESP · Letter to the SECJan 29, 2018
CORRESP · Letter to the SECJan 29, 2018
CORRESP · Letter to the SECJan 19, 2018
CORRESP · Letter to the SECJan 19, 2018
F-1/A · Registration statement, amendedJan 11, 2018
F-1/A · Registration statement, amendedJan 5, 2018
CORRESP · Letter to the SECNov 20, 2017
F-1/A · Registration statement, amendedNov 20, 2017
CORRESP · Letter to the SECNov 17, 2017
UPLOAD · Letter from the SECNov 17, 2017
F-1 · Registration statementNov 9, 2017
DRSLTR · Letter to the SEC with a draftNov 3, 2017
DRS/A · Draft registration statement, amendedNov 3, 2017
UPLOAD · Letter from the SECOct 5, 2017
DRSLTR · Letter to the SEC with a draftSep 20, 2017
DRS/A · Draft registration statement, amendedSep 20, 2017
UPLOAD · Letter from the SECAug 11, 2017
DRS · Draft registration statementJul 14, 2017

Open IPO · From the cover of the final prospectus (424B4) filed Jun 29, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue42.0K181.0K0134.0K571.0K365.0K
Cost of revenue42.0K172.0K0101.0K373.0K300.0K
Gross profit09.00K033.0K198.0K65.0K
Research and development6.00M4.50M4.51M5.85M6.77M6.38M
Selling, general and administrative398.0K340.0K
Operating income-11.5M-9.59M-8.89M-13.0M-12.2M-11.2M
Depreciation and amortization30.0K46.0K56.0K64.0K53.0K63.0K
EBITDA-11.5M-9.54M-8.84M-13.0M-12.2M-11.1M
Income before tax-11.4M-9.53M-8.86M-12.9M-12.2M-11.2M
Income tax014.0K29.0K137.0K-59.0K20.0K
Net income-11.4M-9.54M-8.89M-13.1M-12.2M-11.2M
Earnings per share, basic0.250.250.310.450.470.67
Earnings per share, diluted0.250.250.310.450.470.67

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents7.11M8.66M11.0M12.3M24.9M8.59M
Receivables0126.0K0246.0K183.0K255.0K
Current assets15.3M8.97M11.3M12.8M25.3M9.11M
Property, plant and equipment134.0K57.0K100.0K139.0K156.0K192.0K
Total assets16.0M9.39M11.8M13.1M26.0M9.72M
Accounts payable448.0K132.0K83.0K17.0K166.0K164.0K
Current liabilities2.20M1.18M1.09M1.34M3.16M1.84M
Total liabilities2.89M1.31M1.38M1.37M3.42M2.21M
Shareholders' equity13.1M8.08M10.4M11.8M22.6M7.51M
Shares outstanding46.2M38.8M35.5M28.8M28.8M21.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-7.37M-6.82M-7.31M-12.5M-9.06M-10.6M
Capital spending-107.0K-3.00K-17.0K-47.0K-17.0K-53.0K
Free cash flow-7.48M-6.82M-7.33M-12.5M-9.08M-10.6M
Cash from investing-107.0K-3.00K-17.0K-102.0K-17.0K-53.0K
Cash from financing13.7M4.48M6.04M13.0K25.4M4.05M
Change in cash6.20M-2.35M-1.29M-12.6M16.3M-6.56M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2026Quarterly reportSEC
8-K · Current reportNov 6, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 30, 2026Big-stake noticeSEC
8-K · Current reportOct 27, 2026Management or board changeSEC
DEF 14A · Proxy statementOct 14, 2026Meeting noticeSEC
8-K · Current reportOct 6, 2026Management or board changeSEC
PRE 14A · Preliminary proxy statementSep 23, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveAug 31, 2026Other filingsSEC
424B3 · ProspectusAug 28, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
S-3 · Registration statementAug 21, 2026Offer documentSEC
3 · Initial statement of ownershipAug 21, 2026Insider tradeSEC
8-K · Current reportAug 18, 2026Current reportSEC
DAug 12, 2026Other filingsSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
S-8 · Registration statement for employee plansAug 7, 2026Offer documentSEC
10-Q · Quarterly reportAug 7, 2026Quarterly reportSEC
8-K · Current reportAug 7, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 4, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 4, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeAug 4, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 4, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 4, 2026Big-stake noticeSEC
8-K · Current reportJul 28, 2026Material contractSEC
8-K · Current reportJul 16, 2026Management or board changeSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
DEFA14A · Additional proxy materialJun 3, 2026Meeting noticeSEC
ARS · Annual report to shareholdersJun 3, 2026Annual reportSEC
DEF 14A · Proxy statementJun 3, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveMay 18, 2026Other filingsSEC
424B3 · ProspectusMay 15, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementMay 14, 2026Meeting noticeSEC
CORRESP · Letter to the SECMay 13, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 12, 2026Other filingsSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
S-3 · Registration statementMay 8, 2026Offer documentSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
8-K · Current reportMay 8, 2026ResultsSEC
8-K · Current reportApr 3, 2026Material contractSEC
10-K · Annual reportMar 27, 2026Annual reportSEC
8-K · Current reportMar 27, 2026ResultsSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
8-K · Current reportMar 4, 2026Current reportSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 9, 2026Insider tradeSEC
8-K · Current reportFeb 9, 2026Management or board changeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
8-K · Current reportFeb 4, 2026Material contractSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportNov 14, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 8, 2025Quarterly reportSEC
8-K · Current reportAug 8, 2025ResultsSEC
8-K · Current reportJul 28, 2025Current reportSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
8-K · Current reportJul 18, 2025Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveJun 9, 2025Other filingsSEC
424B3 · ProspectusJun 6, 2025Offer documentSEC
DEFA14A · Additional proxy materialJun 5, 2025Meeting noticeSEC
ARS · Annual report to shareholdersJun 5, 2025Annual reportSEC
DEF 14A · Proxy statementJun 5, 2025Meeting noticeSEC
CORRESP · Letter to the SECJun 4, 2025Other filingsSEC
UPLOAD · Letter from the SECJun 4, 2025Other filingsSEC
S-8 · Registration statement for employee plansMay 30, 2025Offer documentSEC
S-3 · Registration statementMay 30, 2025Offer documentSEC
UPLOAD · Letter from the SECMay 23, 2025Other filingsSEC
3 · Initial statement of ownershipMay 20, 2025Insider tradeSEC
CORRESP · Letter to the SECMay 20, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementMay 14, 2025Meeting noticeSEC
10-Q · Quarterly reportMay 9, 2025Quarterly reportSEC
8-K · Current reportMay 9, 2025ResultsSEC
UPLOAD · Letter from the SECMay 6, 2025Other filingsSEC
4 · Change in ownershipApr 30, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 2, 2025Big-stake noticeSEC
10-K · Annual reportMar 28, 2025Annual reportSEC
8-K · Current reportMar 28, 2025ResultsSEC
8-K · Current reportMar 17, 2025Material contractSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
8-K · Current reportJan 10, 2025Current reportSEC
424B5 · ProspectusJan 10, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeJan 6, 2025Big-stake noticeSEC
8-K/A · Current report, amendedDec 20, 2024Meeting outcomeSEC
3 · Initial statement of ownershipNov 20, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 20, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 8, 2024Quarterly reportSEC
8-K · Current reportNov 8, 2024ResultsSEC
4 · Change in ownershipOct 4, 2024Insider tradeSEC
4 · Change in ownershipOct 4, 2024Insider tradeSEC
4 · Change in ownershipOct 4, 2024Insider tradeSEC
4 · Change in ownershipOct 4, 2024Insider tradeSEC
4 · Change in ownershipOct 4, 2024Insider tradeSEC
4 · Change in ownershipAug 29, 2024Insider tradeSEC
4 · Change in ownershipAug 29, 2024Insider tradeSEC
4 · Change in ownershipAug 29, 2024Insider tradeSEC
4 · Change in ownershipAug 29, 2024Insider tradeSEC
4 · Change in ownershipAug 29, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedAug 20, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 9, 2024Offer documentSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
8-K · Current reportAug 9, 2024ResultsSEC
8-K · Current reportAug 2, 2024Meeting outcomeSEC
4/A · Change in ownership, amendedAug 2, 2024Insider tradeSEC
4 · Change in ownershipAug 2, 2024Insider tradeSEC
DEFA14A · Additional proxy materialJun 20, 2024Meeting noticeSEC
ARS · Annual report to shareholdersJun 20, 2024Annual reportSEC
DEF 14A · Proxy statementJun 20, 2024Meeting noticeSEC
3 · Initial statement of ownershipJun 7, 2024Insider tradeSEC
PRE 14A · Preliminary proxy statementMay 29, 2024Meeting noticeSEC
10-Q · Quarterly reportMay 10, 2024Quarterly reportSEC
8-K · Current reportMay 10, 2024ResultsSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMar 8, 2024Offer documentSEC
10-K · Annual reportMar 8, 2024Annual reportSEC
8-K · Current reportMar 8, 2024ResultsSEC
8-K · Current reportMar 4, 2024Current reportSEC
424B3 · ProspectusFeb 15, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 15, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 14, 2024Other filingsSEC
S-3/A · Registration statement, amendedFeb 14, 2024Offer documentSEC
8-K · Current reportFeb 2, 2024Current reportSEC
S-3 · Registration statementFeb 2, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedJan 16, 2024Big-stake noticeSEC
4 · Change in ownershipJan 16, 2024Insider tradeSEC
4 · Change in ownershipJan 11, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
8-K · Current reportJan 3, 2024Current reportSEC
DJan 2, 2024Other filingsSEC
4 · Change in ownershipDec 27, 2023Insider tradeSEC
4 · Change in ownershipDec 27, 2023Insider tradeSEC
8-K · Current reportDec 26, 2023Material contractSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
4 · Change in ownershipSep 14, 2023Insider tradeSEC
4 · Change in ownershipSep 14, 2023Insider tradeSEC
8-K · Current reportSep 13, 2023Meeting outcomeSEC
4 · Change in ownershipAug 24, 2023Insider tradeSEC
3 · Initial statement of ownershipAug 24, 2023Insider tradeSEC
4 · Change in ownershipAug 23, 2023Insider tradeSEC
4 · Change in ownershipAug 22, 2023Insider tradeSEC
ARS · Annual report to shareholdersAug 15, 2023Annual reportSEC
DEF 14A · Proxy statementAug 15, 2023Meeting noticeSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
8-K · Current reportAug 11, 2023ResultsSEC
PRER14AJul 28, 2023Other filingsSEC
8-K · Current reportJun 30, 2023Current reportSEC
25-NSE/AJun 29, 2023Other filingsSEC
8-K · Current reportJun 27, 2023Current reportSEC
PRE 14A · Preliminary proxy statementJun 23, 2023Meeting noticeSEC
8-K · Current reportJun 7, 2023Management or board changeSEC
S-8 · Registration statement for employee plansJun 2, 2023Offer documentSEC
10-Q · Quarterly reportMay 5, 2023Quarterly reportSEC
8-K · Current reportMay 5, 2023ResultsSEC
4 · Change in ownershipApr 25, 2023Insider tradeSEC
4 · Change in ownershipApr 25, 2023Insider tradeSEC
4 · Change in ownershipApr 25, 2023Insider tradeSEC
4 · Change in ownershipApr 6, 2023Insider tradeSEC
10-K · Annual reportMar 31, 2023Annual reportSEC
8-K · Current reportMar 31, 2023ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC

This page holds 200 of 421 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Entera Bio Ltd.’s releases · as of Aug 7, 2026

Common shares
173,922,428
Fully diluted
173,922,428

Fully diluted

LineShares
Common shares173,922,428

Share count over time

CountShares
Nov 22, 2026173,922,428

Open Cap table

Shareholders

HolderSharesValueAs of
Fidelity Nasdaq Composite Index Fund29,908US$40,376May 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Steve Rubin
Other companies: Red Violet, Inc. (Director · Since at least Mar 26, 2018); Niagen Bioscience, Inc. (Director · Since at least Mar 27, 2017); Cocrystal Pharma, Inc. (Director · Since at least Mar 17, 2014); OPKO Health, Inc. (Executive VP-Administration, Director · Since at least Feb 9, 2007); VBI Vaccines Inc. (Director · Dec 31, 2016 – Jun 14, 2018 · Past); Fluent, Inc. (Director · Jan 11, 2010 – Apr 13, 2017 · Past); PROLOR Biotech Inc (Director · Jul 23, 2009 – Aug 29, 2013 · Past); Castle Brands Inc (Director · Jan 21, 2009 – Oct 8, 2019 · Past); Non-Invasive Monitoring Systems, Inc. (Director · Oct 30, 2008 – Feb 28, 2012 · Past); BioCardia, Inc. (Interim CEO and Interim CFO, Director · Sep 19, 2008 – Aug 11, 2016 · Past); Asensus Surgical Inc (Director · Sep 4, 2007 – Apr 23, 2013 · Past); Dreams Inc (Director · Jun 25, 2007 – Jun 19, 2009 · Past)
Director · Since at least Feb 1, 2026
Geno Germano
Other companies: Harmony Biosciences Holdings, Inc. (Director · Since at least Apr 2, 2026); Precision BioSciences, Inc. (Director · Since at least Mar 10, 2020); Sage Therapeutics Inc (Director · Since at least Jun 6, 2018); Bioverativ Inc (Director · Jan 31, 2018 – Mar 8, 2018 · Past); The Medicines Company (Director · Nov 9, 2017 – Jan 6, 2020 · Past)
Chairman of the Board · Since at least Feb 4, 2026
Miranda Toledano
Other companies: Journey Medical Corporation (Director · Since at least Nov 16, 2021); NexGel, Inc (Director · Sep 9, 2021 – Aug 17, 2023 · Past); Compass Therapeutics, Inc. (Director · Jun 25, 2021 – Jun 25, 2021 · Past); Sorrento Therapeutics, Inc. (EVP-Corporate Development · Sep 16, 2016 – Sep 16, 2016 · Past)
Chief Executive Officer and Board Member · Since at least Jan 1, 2022
Gerald Lieberman
Other companies: Teva Pharmaceutical Industries Limited (Independent Director · Since at least Jan 1, 2018); Forest Laboratories Inc (Director · Aug 23, 2011 – Jul 1, 2014 · Past); AllianceBernstein Holding L.P. (President and COO, Director · Feb 3, 2006 – Jan 23, 2009 · Past)
Director · Since at least Jan 1, 2022
Ron Mayron
Other companies: IceCure Medical Ltd. (Chairman of the Board · Since at least Mar 18, 2026); Big Digital Energy, Inc. (Director · Nov 16, 2017 – Apr 4, 2018 · Past)
Director · Jan 1, 2022 – Jan 1, 2024 · Past
Roger Garceau
Other companies: Protara Therapeutics, Inc. (Director · Since at least Jan 9, 2020)
Director · Jan 1, 2022 – Jan 1, 2024 · Past
Yonatan Malca
Other companies: IceCure Medical Ltd. (Director · Since at least Mar 18, 2026)
Director · Since at least Jan 1, 2024
Anke HoppeVP of Clinical Operations · Since at least Nov 5, 2026
Arthur C Santora IIChief Medical Officer · Jan 1, 2022 – Apr 24, 2023 · Past
Cherin SmithSVP Clinical Operations · Since at least May 9, 2025
All 26 people
PersonSeat
Dana-Garbeli YaacovChief Financial Officer · Since at least Nov 5, 2026
Dana Yaacov-GarbeliChief Financial Officer · Since at least Jan 1, 2022
Gerald M. OstrovBoard Member · Since at least Jan 2, 2023
Gregory BurshteinChief Scientific Officer · Since at least May 28, 2024
Haya TaitelBoard Member · Since at least Jun 4, 2023
Hillel GalitzerChief Operating Officer · Since at least Mar 31, 2022
Leslie Velka GautamChief Business Officer · May 8, 2025 – May 8, 2025 · Past
Michal KushnirHead of Program Management · Since at least Nov 5, 2026
Michele McDermottSVP Medical Affairs · Since at least Nov 5, 2026
Osnat Bar-PeledExecutive Director of IP · Since at least Nov 5, 2026
Phillip SchwartzPresident of R&D, Director · Jan 1, 2022 – Jan 20, 2022 · Past
Rachel B. WagmanChief Clinical Advisor · Since at least Oct 13, 2026
Ramesh RatanU.S.based CFO · Jan 1, 2022 – Jan 19, 2022 · Past
Riccardo Paolo CamisascaChief Medical Officer · Since at least Aug 18, 2026
Sean EllisBoard Member · Since at least Jan 1, 2022
Spiros JamasChief Executive Officer · Jan 1, 2022 – Jan 18, 2022 · Past

Open People

Log in to ask 6ix AI your own questions about Entera Bio Ltd.